Paulo H. M. Chaves

Dr. Paulo H. M. Chaves

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2022 in European Heart Journal
Verified
Journal Article
Open access
PDF file
CEChristina M Eckhardt
Christina M Eckhardt
PBPallavi P Balte
Pallavi P Balte
RBRobert Graham Barr
Robert Graham Barr
ABAlain G Gerald Bertoni
Alain G Gerald Bertoni
SBSurya P Bhatt
Surya P Bhatt
EOElizabeth C Oelsner
Elizabeth C Oelsner
Aims: The aim is to evaluate associations of lung function impairment with risk of incident heart failure (HF). Methods and results: Data were pooled across eight US population-based cohorts that enrolled participants from 1987 to 2004. Participants with self-reported baseline cardiovascular disease were excluded. Spirometry was used to define obstructive [forced expiratory volume in 1 s/forced vital capacity (FEV1/FVC) <0.70] or restrictive (FEV1/FVC ≥0.70, FVC <80%) lung physiology. The incident HF was defined as hospitalization or death caused by HF. In a sub-set, HF events were sub-classified as HF with reduced ejection fraction (HFrEF; EF <50%) or preserved EF (HFpEF; EF ≥50%). The Fine–Gray proportional sub-distribution hazards models were adjusted for sociodemographic factors, smoking, and cardiovascular risk factors. In models of incident HF sub-types, HFrEF, HFpEF, and non-HF mortality were treated as competing risks. Among 31 677 adults, there were 3344 incident HF events over a median follow-up of 21.0 years. Of 2066 classifiable HF events, 1030 were classified as HFrEF and 1036 as HFpEF. Obstructive [adjusted hazard ratio (HR) 1.17, 95% confidence interval (CI) 1.07–1.27] and restrictive physiology (adjusted HR 1.43, 95% CI 1.27–1.62) were associated with incident HF. Obstructive and restrictive ventilatory defects were associated with HFpEF but not HFrEF. The magnitude of the association between restrictive physiology and HFpEF was similar to associations with hypertension, diabetes, and smoking. Conclusion: Lung function impairment was associated with increased risk of incident HF, and particularly incident HFpEF, independent of and to a similar extent as major known cardiovascular risk factors.

10 June 2023 in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
Verified
Journal Article
Closed access
PDF file
JRJulie Richardson
Julie Richardson
MBMarla Beauchamp
Marla Beauchamp
JBJonathan Bean
Jonathan Bean
JBJennifer Brach
Jennifer Brach
PCPaulo H. M. Chaves
Paulo H. M. Chaves
SMShaghayegh Mirbaha
Shaghayegh Mirbaha
Background: Early change in function in older adults has been termed preclinical disability (PCD). PCD has been understudied compared to other stages of disability because it is unlikely to receive comparative priority in clinical settings. It has major implications for prevention and population health as it may be the optimal time to intervene to prevent further decline. A standardized approach to research in PCD, including a common definition and measurement approaches, is needed to advance this work. Methods: The process to establish how PCD should be defined and measured was undertaken in 2 stages: (1) a scoping review of the literature, which was used to inform (2) a web-enabled consensus meeting with content experts. Results: The scoping review and the consensus meeting support the use of the term preclinical mobility limitation (PCML) and that it should be measured using both patient-reported and performance-based measures. It was agreed that the definition of PCML should include modification of frequency and/or method of task completion, without overt disability, and that requisite mobility tasks include walking (distance and speed), stairs, and transfers. Conclusions: Currently, there are few standardized assessments that can identify PCML. PCML is the term that most clearly describes the stage where people experience a change in routine mobility tasks, without a perception of disability. Further evaluation into the reliability, validity, and responsiveness of outcome measures is needed to advance research on PCML.

4 March 2023 in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
Verified
Journal Article
Closed access
PDF file
RARyan M Andrews
Ryan M Andrews
ISIlya Shpitser
Ilya Shpitser
VDVanessa Didelez
Vanessa Didelez
PCPaulo H. M. Chaves
Paulo H. M. Chaves
OLOscar L Lopez
Oscar L Lopez
MCMichelle C Carlson
Michelle C Carlson
Background: An important epidemiological question is understanding how vascular risk factors contribute to cognitive impairment. Using data from the Cardiovascular Health Cognition Study, we investigated how subclinical cardiovascular disease (sCVD) relates to cognitive impairment risk and the extent to which the hypothesized risk is mediated by the incidence of clinically manifested cardiovascular disease (CVD), both overall and within apolipoprotein E-4 (APOE-4) subgroups. Methods: We adopted a novel “separable effects” causal mediation framework that assumes that sCVD has separably intervenable atherosclerosis-related components. We then ran several mediation models, adjusting for key covariates. Results: We found that sCVD increased overall risk of cognitive impairment (risk ratio [RR] = 1.21, 95% confidence interval [CI]: 1.03, 1.44); however, there was little or no mediation by incident clinically manifested CVD (indirect effect RR = 1.02, 95% CI: 1.00, 1.03). We also found attenuated effects among APOE-4 carriers (total effect RR = 1.09, 95% CI: 0.81, 1.47; indirect effect RR = 0.99, 95% CI: 0.96, 1.01) and stronger findings among noncarriers (total effect RR = 1.29, 95% CI: 1.05, 1.60; indirect effect RR = 1.02, 95% CI: 1.00, 1.05). In secondary analyses restricting cognitive impairment to only incident dementia cases, we found similar effect patterns. Conclusions: We found that the effect of sCVD on cognitive impairment does not seem to be mediated by CVD, both overall and within APOE-4 subgroups. Our results were critically assessed via sensitivity analyses, and they were found to be robust. Future work is needed to fully understand the relationship between sCVD, CVD, and cognitive impairment.

29 May 2024
Verified
Book Chapter
Closed access
PDF file
PCPaulo H. M. Chaves
Paulo H. M. Chaves
MVMarcia Varella
Marcia Varella

1 April 2021 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
MRMarco Ruiz
Marco Ruiz
ACAdrian Cristian
Adrian Cristian
PCPaulo H. M. Chaves
Paulo H. M. Chaves

1 May 2023
Verified
Conference Paper
Closed access
SBSurya Bhatt
Surya Bhatt
YSY. Sun
Y. Sun
CWC. Wu
C. Wu
PBP.P. Balte
P.P. Balte
JSJ.E. Schwartz
J.E. Schwartz
EOE.C. Oelsner
E.C. Oelsner